Antibody Derivatives As Molecular Agents for Neoplastic Targeting Consortium (ADAMANT)

Research Areas

- Tool Development
  - Innovation
- Biomarker Research
  - Disease Progression, Drug
- Product Development
  - Drugs

At a Glance

- Status: Completed Consortium
- Year Launched: 2008
- Initiating Organization: The European Union Seventh Framework Programme
- Initiator Type: Government
- Location: Europe

Abstract

Under the umbrella of ADAMANT (Antibody Derivatives As Molecular Agents for Neoplastic Targeting), nine teams from six European countries - comprising research institutes, universities, hospitals, foundations, and small enterprises - pursued research aimed at the discovery of improved anticancer therapies, which rely on the antibody-based delivery of cytotoxic agents, radionuclides or immunostimulatory cytokines to tumour cells. The premise guiding the ADAMANT research consortium’s efforts is that this targeted approach of administration spares normal tissues, reduces toxicity, and achieves unprecedented efficacy. The project has built on a multidisciplinary approach involving an already consolidated team of chemists, pharmacologists, clinicians, and clinical researchers, and endeavoured to bring the selected antibody + drug complexes from the basic research setting to the initial phases of clinical investigation.

Mission
Bearing in mind the 7-10 year time span normally needed to move a prospective agent through the pipeline and into clinical use, the benchmark of the project’s success - be the transfer of at least one antibody-based tumour targeting agent to initial clinical studies - has been reached.

Consortium History

Began on April 1, 2008.

Structure & Governance

The project is governed by a consolidated team of chemists, pharmacologists, clinicians, and clinical researchers that represent different participating organizations.

Financing

Three-year € 3,000,000 research project funded under the European Union’s Seventh Framework Programme (FP7)

Intellectual Property

To view the research performed by ADAMANT Consortium, you must be a member.

Impact/Accomplishment
For a summary of the final report, published in 2011, click here

Links/Social Media Feed


Points of Contact

For information regarding ADAMANT, contact The European Union Commission directly

Sponsors & Partners

Raffaella Giavazzi,  Coordinator, Istituto di Ricerche Farmacologiche Mario Negri
Dario Neri, ETH Zurich
Alex Berndt, Friedrich-Schiller-Universität
Matteo Zanda, Kemotech Srl
Eveline Trachsel, Philochem
Silvia Marsoni, SENDO Foundation
Barbara Pedley, University College London
Vincent Castronovo, Università de Liège
Guus Van Dongen, VU University Medical Center

Updated: 06/19/2017